IRADIMED CORP
For the period ended Dec 31, 2023. Filed Mar 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Winter Springs, State of Florida, on March 1, 2024.
| IRADIMED CORPORATION | |
| (Registrant) | |
| | |
|---|---|
| Dated: March 1, 2024 | /s/ Roger Susi |
| By: Roger Susi | |
| Chief Executive Officer and President | |
| (Principal Executive Officer) |
Each person whose signature appears below constitutes and appoints Roger Susi and John Glenn as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company in the capacities and on the dates indicated.
| Signature | Title | Date | ||
|---|---|---|---|---|
| /s/ Roger Susi | Chairman of the Board, Chief Executive Officer and President | March 1, 2024 | ||
| Roger Susi | (Principal Executive Officer) | |||
| | | | | |
| /s/ John Glenn | Chief Financial Officer and Secretary | March 1, 2024 | ||
| John Glenn | (Principal Financial and Accounting Officer) | |||
| | | | | |
| /s/ Monty Allen | Director | March 1, 2024 | ||
| Monty Allen | ||||
| | | | | |
| /s/ Anthony Vuoto | Director | March 1, 2024 | ||
| Anthony Vuoto | ||||
| | | | | |
| /s/ James Hawkins | Director | March 1, 2024 | ||
| James Hawkins | ||||
| | | | | |
| /s/ Hilda Scharen-Guivel | | Director | | March 1, 2024 |
| Hilda Scharen-Guivel | | | | |
IRADIMED CORPORATION FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.